You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Improving Outcomes and Quality of Life in Advanced GIST: Discussing the Patient Journey and the Latest Data

  • Authors: Sara Rothschild, MPH; Margaret von Mehren, MD; Jean-Yves Blay, MD​; Richard F. Riedel, MD; Olivia Franek, BSN, RN, OCN
  • CME / ABIM MOC / CE Released: 12/19/2022
  • Valid for credit through: 12/19/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    Nurses - 0.75 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    IPCE: 0.75 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for a global audience of hematologists/oncologists, gastroenterologists, pathologists, nurses, nurse practitioners, and other healthcare professionals involved in the care of patients with GIST.

The goal of this activity is for learners to better be able to apply the latest advances for the treatment of advanced GIST, including as part of a multidisciplinary team, to improve patient outcomes and quality of life.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Different safety profiles of the available treatments for advanced GIST
  • Have greater competence related to
    • Applying team-based best practices for improving quality of life of patients with GIST
  • Demonstrate greater confidence in their ability to
    • Understand the implications of the latest data for patients with advanced GIST


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Sara Rothschild, MPH

    Patient Advocate
    Executive Director
    The Life Raft Group
    Wayne, New Jersey, United States

    Disclosures

    Sara Rothschild, MPH, has no relevant financial relationships.

  • Margaret von Mehren, MD

    Professor of Medical Oncology
    Chief of the Division of Sarcoma Medical Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania, United States

    Disclosures

    Margaret von Mehren, MD, has the following relevant financial relationships:
    Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.; Deciphera Pharmaceuticals, Inc.; GlaxoSmithKline   
    Research funding from:  Cogent; Deciphera Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis; Solarius; Theseus; Tomito

  • Jean-Yves Blay, MD

    Professor of Medical Oncology
    President, UNICANCER
    General Director, Centre Léon Bérard
    French Sarcoma Group
    Académie Nationale de Médecine
    LYRICAN, NETSARC, ERN EURACAN
    Lyon, France

    Disclosures

    Jean-Yves Blay, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bayer; Deciphera Pharmaceuticals, Inc.; Roche
    Research funding from: AstraZeneca Pharmaceuticals LP; Bayer; Blueprint; Bristol Myers Squibb Company; Deciphera Pharmaceuticals, Inc.; GlaxoSmithKline; Merck Sharp & Dohme GmbH; Novartis; Roche
    Executive role with: Transgene

  • Richard F. Riedel, MD

    Associate Professor of Medicine
    Duke Cancer Institute
    Duke University Health System
    Durham, North Carolina, United States

    Disclosures

    Richard F. Riedel, MD, has the following relevant financial relationships:
    Consultant or advisor for: AADi; Blueprint; NanoCarrier; SpringWorks     
    Research funding from: AADi; AROG; Ayala; BioAtla; Cogent Biosciences; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals; GlaxoSmithKline; Karyopharm; Ignyta Inc.; Immune Design; Inhibrx; Lilly; NanoCarrier Co., Ltd.; Novartis; Oncternal; Philogen S.p.A.; Plexxikon Inc.; PTC Therapeutics; Roche; SpringWorks; Threshold Pharmaceuticals; Tracon Pharmaceuticals, Inc.; Trillium

  • Olivia Franek, BSN, RN, OCN

    Sarcoma Oncology Nurse
    Duke Cancer Institute
    Duke University Health System
    Durham, North Carolina, United States

    Disclosures

    Olivia Franek, BSN, RN, OCN, has no relevant financial relationships.

Editors

  • Keisha Peters

    ​Medical Education Director, Medscape, LLC 

    Disclosures

    ​Keisha Peters has no relevant financial relationships. 

  • ​Eloise Ballard, PhD

    ​Scientific Content Manager, Medscape, LLC 

    Disclosures

    ​Eloise Ballard, PhD, has no relevant financial relationships.​​ 

​​Compliance Reviewer/Nurse Planner

  • ​Lisa Simani, APRN, MS, ACNP

    ​​Associate Director, Accreditation and Compliance, Medscape, LLC​ 

    Disclosures

    ​Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.​​​ 

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Improving Outcomes and Quality of Life in Advanced GIST: Discussing the Patient Journey and the Latest Data

Authors: Sara Rothschild, MPH; Margaret von Mehren, MD; Jean-Yves Blay, MD​; Richard F. Riedel, MD; Olivia Franek, BSN, RN, OCNFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/19/2022

Valid for credit through: 12/19/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Challenges Faced by Patients During Their Treatment Journey With GIST

Listen to our expert faculty discuss the importance of empowering patients throughout their treatment journey.
Sara Rothschild, MPH

Digesting the Data From The Latest Congresses

Listen to our expert faculty discuss the latest data on the management of GIST from ESMO and ASCO 2022.
Jean-Yves Blay, MD

Selecting and Sequencing Treatment in GIST: What Are the Latest Recommendations?

Join our expert panel as they discuss the latest recommendations and treatment approaches in GIST.
Margaret von Mehren, MD and Jean-Yves Blay, MD

Safety Profile, Adverse Event Management, and Patient Considerations: Applying Best Practices in GIST

Join our expert panel as they discuss the management of adverse events with TKIs in GIST.
Margaret von Mehren, MD and Richard F. Riedel, MD

Communicating With the Patient: Discussing the Role of the Clinician and the Nurse

Listen to our expert panel as they discuss the importance of open communication in the management of patients with GIST.
Richard F. Riedel, MD and Olivia Franek, BSN, RN, ONC
 

Educational Impact Challenge

The goal of this activity is for learners to better be able to apply the latest advances for the treatment of advanced GIST, including as part of a multidisciplinary team, to improve patient outcomes and quality of life.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print